LU91867I9 - - Google Patents

Info

Publication number
LU91867I9
LU91867I9 LU91867C LU91867C LU91867I9 LU 91867 I9 LU91867 I9 LU 91867I9 LU 91867 C LU91867 C LU 91867C LU 91867 C LU91867 C LU 91867C LU 91867 I9 LU91867 I9 LU 91867I9
Authority
LU
Luxembourg
Application number
LU91867C
Other versions
LU91867I2 (fr
Inventor
Alan Edward Royce
Tomoyuki Oomura
Madhusudhan Pudipeddi
Colleen Ruegger
Masaki Sasaki
Tokuhiro Tamura
Original Assignee
Novartis Ag
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US46121503P priority Critical
Priority to PCT/EP2004/003656 priority patent/WO2004089341A1/fr
Application filed by Novartis Ag, Mitsubishi Tanabe Pharma Corp filed Critical Novartis Ag
Publication of LU91867I2 publication Critical patent/LU91867I2/fr
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91867(I9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of LU91867I9 publication Critical patent/LU91867I9/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
LU91867C 2003-04-08 2011-09-08 LU91867I9 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US46121503P true 2003-04-08 2003-04-08
PCT/EP2004/003656 WO2004089341A1 (fr) 2003-04-08 2004-04-06 Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre

Publications (2)

Publication Number Publication Date
LU91867I2 LU91867I2 (fr) 2011-11-08
LU91867I9 true LU91867I9 (fr) 2019-01-03

Family

ID=32326722

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91867C LU91867I9 (fr) 2003-04-08 2011-09-08

Country Status (43)

Country Link
US (9) US20060275357A1 (fr)
EP (5) EP2008650A3 (fr)
JP (3) JP5495467B2 (fr)
KR (3) KR101367574B1 (fr)
CN (2) CN1767819B (fr)
AR (3) AR043987A1 (fr)
AT (3) AT501681B1 (fr)
AU (1) AU2004228929B2 (fr)
BE (1) BE1015972A5 (fr)
BR (1) BRPI0409250A (fr)
CA (2) CA2707750A1 (fr)
CL (2) CL2004000745A1 (fr)
CY (2) CY1110260T1 (fr)
DE (4) DE102004016947A1 (fr)
DK (2) DK1613288T3 (fr)
EC (1) ECSP056090A (fr)
ES (3) ES2320767T3 (fr)
FR (1) FR2854073B1 (fr)
GB (1) GB2400318B (fr)
GR (1) GR1005052B (fr)
HK (3) HK1071685A1 (fr)
HR (3) HRP20050886B1 (fr)
HU (2) HUE028247T2 (fr)
IE (1) IE20040246A1 (fr)
IL (3) IL170888A (fr)
IS (2) IS2682B (fr)
IT (1) ITMI20040682A1 (fr)
LU (1) LU91867I9 (fr)
MA (1) MA27729A1 (fr)
MX (1) MXPA05010860A (fr)
MY (1) MY141249A (fr)
NO (4) NO329332B1 (fr)
NZ (3) NZ592339A (fr)
PE (5) PE20050396A1 (fr)
PL (2) PL2316431T3 (fr)
PT (1) PT1613288E (fr)
RU (5) RU2358716C2 (fr)
SG (1) SG175449A1 (fr)
SI (2) SI1613288T1 (fr)
TN (1) TNSN05256A1 (fr)
TW (1) TWI332847B (fr)
WO (1) WO2004089341A1 (fr)
ZA (1) ZA200507394B (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1773307E (pt) * 2004-07-30 2015-01-14 Novartis Ag Formulações de compostos à base de 2-amino-1,3- propanodiol
CN1891212B (zh) 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
DK2295049T3 (en) * 2005-09-09 2015-02-23 Novartis Ag Treatment of autoimmune diseases
MX2008006090A (es) 2005-11-09 2008-10-23 Proteolix Inc Compuestos para inhibicion de la enzima.
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
ES2415632T3 (es) 2006-06-19 2013-07-26 Onyx Therapeutics, Inc. Epoxicetonas peptídicas para la inhibición del proteosoma
EP1923058A1 (fr) * 2006-09-26 2008-05-21 Novartis AG Composition pharmaceutique enrobée comprenant un agoniste ou un modulateur de S1P
EP1905434A1 (fr) * 2006-09-26 2008-04-02 Novartis AG Compositions organiques comprenant d'un agoniste de S1P recepteur et leur utilisation therapeutique
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
KR20090057399A (ko) 2006-09-26 2009-06-05 노파르티스 아게 S1p 조정제를 포함하는 제약 조성물
EP1923054A1 (fr) * 2006-09-26 2008-05-21 Novartis AG Composition pharmaceutique à désintégration rapide comprenant un agoniste ou modulateur de S1P
EP1923055A1 (fr) * 2006-09-26 2008-05-21 Novartis AG Composition pharmaceutique lyophilisée comprenant un agoniste ou modulateur de S1P
WO2008124210A1 (fr) * 2007-02-14 2008-10-16 Emory University Procédés et compositions destinés à traiter ou prévenir une infection en utilisant des agents de séquestration des leucocytes
EP2140867B1 (fr) 2007-03-29 2017-08-30 Daiichi Sankyo Company, Limited Composition pharmaceutique
MY166950A (en) 2007-10-04 2018-07-25 Onyx Therapeutics Inc Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
EP2209493A2 (fr) 2007-10-12 2010-07-28 Novartis AG Compositions comprenant des modulateurs du récepteur de sphingosine 1-phosphate (s1p)
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
WO2009099174A1 (fr) 2008-02-07 2009-08-13 Kyorin Pharmaceutical Co., Ltd. Agent thérapeutique ou agent préventif pour maladie inflammatoire des intestins contenant un dérivé d'alcool aminé comme composant actif
CN104800208A (zh) 2008-03-17 2015-07-29 埃科特莱茵药品有限公司 受体激动剂的给药方案
KR20180017232A (ko) 2008-06-20 2018-02-20 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
BRPI0914164B1 (pt) * 2008-06-20 2019-04-30 Merck Patent Gmbh Comistura para produção de comprimidos de desintegração rápida em um processo de formação de comprimido direto, seus usos, e formulações de comprimido
PL2334202T3 (pl) * 2008-09-04 2012-04-30 Cargill, Incorporated Tabletkowanie erytrytolu
CN102256616A (zh) 2008-10-21 2011-11-23 欧尼斯治疗公司 与肽环氧酮的联合疗法
KR20110086142A (ko) 2008-11-11 2011-07-27 노파르티스 아게 핑골리모드의 염
KR20130109254A (ko) * 2008-11-11 2013-10-07 노파르티스 아게 핑골리모드 hcl의 결정질 형태
AU2013100531B4 (en) * 2008-11-11 2013-11-28 Novartis Ag Crystalline forms of fingolimod HCL
CA2747427C (fr) 2008-12-17 2015-10-13 Daiichi Sankyo Company, Limited Methode de production d'un derive de diamine
EP2383272A4 (fr) 2009-01-13 2012-07-25 Daiichi Sankyo Co Ltd Inhibiteur d'un facteur actif de la coagulation sanguine
EP2407457B1 (fr) 2009-03-10 2015-04-22 Daiichi Sankyo Company, Limited Procédé de production d'un dérivé de diamine
CN102348680B (zh) 2009-03-13 2014-11-05 第一三共株式会社 用于制备光学活性二胺衍生物的方法
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
ES2605034T3 (es) * 2009-06-18 2017-03-10 Daiichi Sankyo Company, Limited Composición farmacéutica con solubilidad mejorada
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
WO2011109355A1 (fr) 2010-03-01 2011-09-09 Onyx Therapeutics, Inc. Composés pour inhibition de l'immunoprotéasome
JP5692873B2 (ja) 2010-03-19 2015-04-01 第一三共株式会社 ジアミン誘導体の結晶およびその製造方法
CA2793525C (fr) 2010-03-19 2014-05-06 Daiichi Sankyo Company, Limited Procede d'amelioration de la dissolution d'un agent anticoagulant
WO2011131368A2 (fr) * 2010-04-22 2011-10-27 Ratiopharm Gmbh Procédé de préparation d'une forme galénique orale comprenant du fingolimod
WO2012002538A1 (fr) 2010-07-02 2012-01-05 第一三共株式会社 Procédé pour la préparation de sel dérivé de diamine optiquement actif
US9266816B2 (en) 2010-11-25 2016-02-23 Shilpa Medicare Limited Fingolimod polymorphs and their processes
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
EA028950B1 (ru) * 2011-08-01 2018-01-31 Тева Фармасьютикал Индастриз Лтд. Способ получения фармацевтических композиций, содержащих финголимод
BR112014002397A2 (pt) 2011-08-10 2017-02-21 Daiichi Sankyo Co Ltd composição farmacêutica contendo derivado de diamina
WO2013091704A1 (fr) 2011-12-22 2013-06-27 Synthon Bv Composition pharmaceutique comprenant le fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
US9309283B2 (en) 2012-07-09 2016-04-12 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
BR112015016189A8 (pt) 2013-01-08 2019-10-22 Pathologica Llc usos de metilglioxal bis (guanilhidrazona) (“mgbg”), uso de metilglioxal bis (guanilhidrazona) (“mgbg”) e um agente e composição farmacêutica
WO2014141298A2 (fr) * 2013-03-11 2014-09-18 Astron Research Limited Composition pharmaceutique stable de fingolimod
WO2014175287A1 (fr) * 2013-04-26 2014-10-30 国立大学法人 京都大学 Composition médicinale destinée à empêcher la formation et/ou l'expansion d'un anévrisme cérébral ou réduire un tel anévrisme
WO2013190151A1 (fr) * 2013-05-13 2013-12-27 Synthon B.V. Composition pharmaceutique contenant du fingolimod
US20160128951A1 (en) * 2013-07-29 2016-05-12 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2016026461A1 (fr) * 2014-08-22 2016-02-25 Sunshine Lake Pharma Co., Ltd. Composition solide de fingolimod et préparation associée
WO2016042493A1 (fr) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Compositions pharmaceutiques de fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
WO2016118515A1 (fr) * 2015-01-20 2016-07-28 Handa Pharmaceuticals, Llc Forme galénique solide stable de fingolimod
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
WO2018178744A1 (fr) 2017-03-29 2018-10-04 Deva Holding Anonim Sirketi Formulations stables de fingolimod

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
DE69321823T2 (de) 1992-10-21 1999-06-02 Yoshitomi Pharmaceutical 2-amino-1, 3- propandiolverbindung und immunosuppressium
DE69524962T4 (de) 1994-08-22 2003-08-28 Mitsubishi Pharma Corp Benzolderivate und deren medizinische verwendung
DE69633613D1 (de) 1995-12-28 2004-11-18 Mitsubishi Pharma Corp 2-Amino-2-(2-(4-octylphenyl)ethyl)propan-1,3-diol enthaltendes Arzneimittel zur topischen Anwendung zur Behandlung von Erkrankungen die durch eine Störung des Immunsystems hervorgerufen werden
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
CN1178653C (zh) * 1997-02-27 2004-12-08 三菱制药株式会社 药物组合物
IL155065A (en) * 1997-04-04 2004-01-04 Mitsubishi Pharma Corp 2-aminopropane-1,3-diol derivatives and pharmaceutical compositions containing the same
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) 1999-06-30 2011-02-09 松森  昭 ウイルス性心筋炎の予防または治療薬剤
KR20020027463A (ko) 1999-07-12 2002-04-13 우에노 도시오 스핀고신-1-인산 수용체 아고니스트 또는스핀고신-1-인산을 유효 성분으로서 함유하는 선유화 억제제
KR100812578B1 (ko) 2000-07-13 2008-03-13 상꾜 가부시키가이샤 아미노알코올 유도체
WO2002018395A1 (fr) 2000-08-31 2002-03-07 Merck & Co., Inc. Derives de phosphates utilises en tant qu'agents immuno-regulateurs
SK11942003A3 (sk) 2001-03-26 2004-03-02 Novartis Ag Deriváty 2-aminopropanolu, ich použitie a farmaceutická kompozícia, ktorá ich obsahuje
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
JPWO2003020313A1 (ja) 2001-09-04 2004-12-16 小野薬品工業株式会社 スフィンゴシン−1−リン酸受容体調節剤からなる呼吸器疾患治療剤
EP1431284B1 (fr) 2001-09-27 2007-11-21 Kyorin Pharmaceutical Co., Ltd. Derive de sulfure de diaryle, son sel d'addition et immunosuppresseur
EP1431275B1 (fr) 2001-09-27 2010-04-07 Kyorin Pharmaceutical Co., Ltd. Derive d'ether de diaryle, son sel d'addition et son immunosuppresseur
AU2003202994B2 (en) 2002-01-18 2007-11-22 Merck Sharp & Dohme Corp. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
AU2003214873A1 (en) 2002-01-18 2003-09-02 Ceretek Llc Methods of treating conditions associated with an edg receptor
US7479504B2 (en) 2002-01-18 2009-01-20 Merck & Co., Inc. Edg receptor agonists
WO2003061567A2 (fr) 2002-01-18 2003-07-31 Merck & Co., Inc. Antagonistes sélectifs du récepteur s1p1/edg1
US7781617B2 (en) * 2004-07-16 2010-08-24 Kyorin Pharmaceutical Co., Ltd Effective use method of medicaments and method of preventing expression of side effect

Also Published As

Publication number Publication date
TW200503784A (en) 2005-02-01
JP5543298B2 (ja) 2014-07-09
DE202004021680U1 (de) 2010-04-22
CN1767819A (zh) 2006-05-03
SI2316431T1 (sl) 2016-04-29
HRP20100600A2 (xx) 2011-03-31
HUE028247T2 (en) 2016-12-28
DE102004016947A1 (de) 2004-10-21
AU2004228929A1 (en) 2004-10-21
NZ542622A (en) 2009-01-31
LU91867A9 (fr)
PE20150676A1 (es) 2015-05-17
AR078781A2 (es) 2011-11-30
ES2228282A1 (es) 2005-04-01
IE20040246A1 (en) 2004-12-15
HRP20100601B1 (hr) 2016-12-02
AU2004228929B2 (en) 2008-02-07
HUS1100016I1 (hu) 2016-08-29
US20130108675A1 (en) 2013-05-02
IS8885A (is) 2010-02-25
AT501681B1 (de) 2012-04-15
US20080311188A1 (en) 2008-12-18
CN1767819B (zh) 2010-07-28
GR1005052B (el) 2005-11-30
EP2008650A2 (fr) 2008-12-31
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
GB2400318B (en) 2005-08-10
NO20100250L (no) 2006-01-09
AT501681A1 (de) 2006-10-15
BRPI0409250A (pt) 2006-03-28
JP2011006461A (ja) 2011-01-13
HK1155647A1 (zh) 2016-03-24
PL1613288T3 (pl) 2009-07-31
CA2521325A1 (fr) 2004-10-21
CL2004000745A1 (es) 2005-02-11
DE122011100047I1 (de) 2011-12-15
CY1117071T1 (el) 2017-04-05
CA2521325C (fr) 2010-09-14
DE602004017847D1 (de) 2009-01-02
JP2013177404A (ja) 2013-09-09
NO20131287L (no) 2006-01-09
IS8114A (is) 2005-11-01
PE20130200A1 (es) 2013-03-09
AR043987A1 (es) 2005-08-17
US20140255497A1 (en) 2014-09-11
HK1091114A1 (en) 2009-06-26
PE20050396A1 (es) 2005-07-05
PE20131352A1 (es) 2013-11-14
US20190175527A1 (en) 2019-06-13
IS2682B (is) 2010-10-15
RU2358716C2 (ru) 2009-06-20
NO334116B1 (no) 2013-12-16
NO2011016I1 (no) 2011-09-19
US20170290787A1 (en) 2017-10-12
EP2316431A1 (fr) 2011-05-04
ITMI20040682A1 (it) 2004-07-06
LU91867I2 (fr) 2011-11-08
CA2707750A1 (fr) 2004-10-21
NO335120B1 (no) 2014-09-22
FR2854073B1 (fr) 2008-03-14
MXPA05010860A (es) 2006-05-25
NO2011016I2 (no) 2012-08-27
TNSN05256A1 (en) 2007-07-10
EP2316431B1 (fr) 2015-09-30
RU2010147000A (ru) 2012-08-10
MY141249A (en) 2010-03-31
KR20120101148A (ko) 2012-09-12
RU2475236C2 (ru) 2013-02-20
FR2854073A1 (fr) 2004-10-29
EP1613288B1 (fr) 2008-11-19
CN101797241B (zh) 2013-03-27
JP5495467B2 (ja) 2014-05-21
US20090203798A1 (en) 2009-08-13
HRP20100601A2 (xx) 2011-03-31
US8324283B2 (en) 2012-12-04
GB2400318A (en) 2004-10-13
EP1613288A1 (fr) 2006-01-11
JP2004307506A (ja) 2004-11-04
US20060275357A1 (en) 2006-12-07
MA27729A1 (fr) 2006-01-02
IL197578D0 (en) 2011-07-31
NO20055231D0 (no) 2005-11-07
IL242037D0 (en) 2015-11-30
PT1613288E (pt) 2009-02-25
ES2556947T3 (es) 2016-01-21
RU2012148593A (ru) 2014-05-20
EP2769713A1 (fr) 2014-08-27
SI1613288T1 (sl) 2009-04-30
RU2005134173A (ru) 2006-09-10
US20110105620A1 (en) 2011-05-05
NO329332B1 (no) 2010-09-27
KR20110005320A (ko) 2011-01-17
ZA200507394B (en) 2007-03-28
IL197578A (en) 2015-10-29
PE20090743A1 (es) 2009-07-17
HRP20050886A2 (en) 2006-11-30
DK2316431T3 (en) 2016-01-11
ECSP056090A (es) 2006-03-01
GB0407819D0 (en) 2004-05-12
AR078782A2 (es) 2011-11-30
HK1071685A1 (en) 2006-08-04
KR20050121712A (ko) 2005-12-27
TWI332847B (en) 2010-11-11
KR101367574B1 (ko) 2014-02-25
AT504853A2 (de) 2008-08-15
CN101797241A (zh) 2010-08-11
RU2475237C2 (ru) 2013-02-20
ES2320767T3 (es) 2009-05-28
IL170888A (en) 2010-06-16
WO2004089341A1 (fr) 2004-10-21
DK1613288T3 (da) 2009-03-23
GR20040100121A (el) 2004-12-17
RU2010146697A (ru) 2012-05-27
AT414508T (de) 2008-12-15
NZ592339A (en) 2012-09-28
HRP20050886B1 (xx) 2011-01-31
SG175449A1 (en) 2011-11-28
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
EP2319502A1 (fr) 2011-05-11
NZ586280A (en) 2011-12-22
EP2008650A3 (fr) 2011-04-27
RU2009105403A (ru) 2010-08-27
CY1110260T1 (xx) 2014-04-09
ES2228282B1 (es) 2006-02-16
US20140011885A1 (en) 2014-01-09

Similar Documents

Publication Publication Date Title
JP2003008624A5 (fr)
JP2003007755A5 (fr)
JP2003008988A5 (fr)
JP2003008635A5 (fr)
JP2003005903A5 (fr)
JP2003009004A5 (fr)
JP2003000942A5 (fr)
JP2003009546A5 (fr)
JP2003008629A5 (fr)
JP2003006614A5 (fr)
JP2003003863A5 (fr)
JP2003003102A5 (fr)
JP2003000614A5 (fr)
JP2003008565A5 (fr)
JP2003004695A5 (fr)
JP2003003639A5 (fr)
JP2003007978A5 (fr)
JP2003007089A5 (fr)
JP2003007843A5 (fr)
JP2003002639A5 (fr)
JP2003007471A5 (fr)
JP2003000647A5 (fr)
JP2003005979A5 (fr)
JP2003008131A5 (fr)
JP2003002840A5 (fr)